Tag: ENZY

Finance

Biotech Bullish Stocks: Idenix Pharmaceuticals Inc (NASDAQ:IDIX), Enzymotec Ltd (NASDAQ:ENZY), bluebird bio Inc (NASDAQ:BLUE), Athersys, Inc. (NASDAQ:ATHX)

xBoston hedge fund manager Baupost Group grew its portfolio of U.S. stocks by17 percent to $4.14 billion in the first quarter, maintaining large positions in several companies, including Cambridge-based Idenix Pharmaceuticals Inc (NASDAQ:IDIX). Idenix Pharmaceuticals Inc (NASDAQ:IDIX) stock performance was 6.06% in last session and finished the day at $6.03. Traded volume was 789,231 shares in the last session and the average volume of the … Continue reading Biotech Bullish Stocks: Idenix Pharmaceuticals Inc (NASDAQ:IDIX), Enzymotec Ltd (NASDAQ:ENZY), bluebird bio Inc (NASDAQ:BLUE), Athersys, Inc. (NASDAQ:ATHX)

Chris Lewis
Finance

Biotech Losers: Insys Therapeutics Inc (NASDAQ:INSY), Enzymotec Ltd (NASDAQ:ENZY), Geron Corporation (NASDAQ:GERN), Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)

Insys Therapeutics, Inc. (NASDAQ:INSY)’s shares have been under pressure recently on news regarding prescribing patterns for Subsys. The stock price of the company tumbled 17.41% and 15.45% in the last two consecutive trading sessions. Insys Therapeutics Inc (NASDAQ:INSY) stock performance was -15.70% in last session and finished the day at $23.01. Traded volume was 3.24million shares in the last session and the average volume of … Continue reading Biotech Losers: Insys Therapeutics Inc (NASDAQ:INSY), Enzymotec Ltd (NASDAQ:ENZY), Geron Corporation (NASDAQ:GERN), Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)

Mark DeFrance
BioTech

Neptune Technologies & Bioressources-Ord (NASDAQ:NEPT) and Enzymotec Ltd (NASDAQ:ENZY) Conclude Final Patent Infringement Settlement

Neptune Technologies & Bioressources-Ord (NASDAQ:NEPT) and Acasti Pharma Inc (NASDAQ:ACST), a Neptune subsidiary, Sunday night announced that a final and binding patent infringement settlement and license agreement has been signed with Enzymotec Ltd. and Enzymotec Ltd(NASDAQ:ENZY) that resolves the International Trade Commission’s investigation of infringement of Neptune’s composition of matter patents, related federal court actions initiated by Neptune against Enzymotec and its distributors, and various patent review … Continue reading Neptune Technologies & Bioressources-Ord (NASDAQ:NEPT) and Enzymotec Ltd (NASDAQ:ENZY) Conclude Final Patent Infringement Settlement

Chris Lewis
Finance

Biotech Losers: Inovio Pharmaceuticals (NYSEMKT:INO), Oncomed Pharmaceuticals (NASDAQ:OMED), Enzymotec (NASDAQ:ENZY), Veracyte Inc (NASDAQ:VCYT)

Inovio Pharmaceuticals, Inc. (NYSEMKT:INO) announced financial results for the quarter and year ended December 31, 2013. Inovio Pharmaceuticals Inc (NYSEMKT:INO) stock performance was -7.98% in last session and finished the day at $3.23. Traded volume was 10,401,414 million shares in the last session and the average volume of the stock remained 7.79 million shares. The beta of the stock remained 3.69. Inovio Pharmaceuticals Inc (NYSEMKT:INO) … Continue reading Biotech Losers: Inovio Pharmaceuticals (NYSEMKT:INO), Oncomed Pharmaceuticals (NASDAQ:OMED), Enzymotec (NASDAQ:ENZY), Veracyte Inc (NASDAQ:VCYT)

Kristen Barton
BioTech

Biotech Stocks Touching New Lows: Reliv International (NASDAQ:RELV), Can Fite Biopharma (NYSEMKT:CANF), Enzymotec (NASDAQ:ENZY), Pacific Biosciences (NASDAQ:PACB)

An increase in European and U.S. sales helped Reliv International Inc. (NASDAQ:RELV) raise profits by a small amount in the fourth quarter. Reliv International, Inc (NASDAQ:RELV) stock performance was -11.60% in last session and finished the day at $2.03. Traded volume was 64,448.00million shares in the last session and the average volume of the stock remained 10.29K shares. The beta of the stock remained 1.35. … Continue reading Biotech Stocks Touching New Lows: Reliv International (NASDAQ:RELV), Can Fite Biopharma (NYSEMKT:CANF), Enzymotec (NASDAQ:ENZY), Pacific Biosciences (NASDAQ:PACB)

John Bellich
BioTech

Unusual Volume Biotech Stocks: Compugen Ltd (NASDAQ:CGEN), Sinovac Biotech (NASDAQ:SVA), Enzymotec (NASDAQ:ENZY), Cempra (NASDAQ:CEMP)

Over the past three years, using its in-silico discovery platform for predictive drug discovery (i.e. computer models and algorithms), Compugen Ltd. (USA) (NASDAQ:CGEN) has developed a hugely compelling drug Pipeline across several clinical areas. Compugen Ltd. (USA) (NASDAQ:CGEN) stock performance was -20.14% in last session and finished the day at $11.34. Traded volume was 22,668.00 shares in the last session and the average volume of … Continue reading Unusual Volume Biotech Stocks: Compugen Ltd (NASDAQ:CGEN), Sinovac Biotech (NASDAQ:SVA), Enzymotec (NASDAQ:ENZY), Cempra (NASDAQ:CEMP)

Richard Atkins